Pingchuan Pharmaceutical Inc
Undervalued Special Situation |
|
Symbol: |
PGCN |
| 52 Week
Range |
0.15 - 4.00 |
| Shares
Float: |
25,000,000 |
| Current
Price: |
$3.08 |
| 12
Mo.Target Price |
$26.00 |
| Last 7
days gain |
$2.48 |
|
Breaking News Alerts!
Big
News Expected Monday Jun 20th
Value should climb quickly!
PR Newswire (Tue, Jun 14)
Pingchuan Signs Regional Distribution Contract With Beijing
Pingchuan Tianzhi Medical Technology Development Center
EDGAR Online (Mon, May 23)
PINGCHUAN PHARMACEUTICAL INC Files SEC form 10QSB, Quarterly Report
CORPORATE PROFILE
:
Pingchuan Pharmaceutical Inc. (''PGCN'') is a modernized
pharmaceutical manufacturer with first-class medical R&D ability,
pioneered medicine products, and well-established marketing network.
Since its establishment, PGCN has focused its businesses on diabetes
medicine and its medical products. The products of PGCN include
health care products, varieties of medicine, as well as medical
apparatus. Kang Da Glycosuria Capsule is a successful product of
PGCN for treating diabetes, which was first developed in 1998 and
introduced to the market in 2001. PGCN has well-established
marketing network and sale branches, which include about 180,000
retail pharmacies/drugstores across China, agency network in major
cities like Beijing, Shanghai, Guangzhou, and Xi'an, special counter
sale at drug chain stores in key regions, residence community clinic
sale and promotion, as well as internet marketing through the
company's website. The marketing network of PGCN covers more than
50% districts of China and exports to US, Japan, Russia, and
south-eastern Asia.
About Beijing Pingchuan Tianzhi Medical Technology Development
Center
Beijing Pingchuan Tianzhi Medical Technology Development is grouped
under Harbin Pingchuan Pharmaceutical Co., Ltd. in Jan. 2000. It is
a wholly-owned subsidiary of Harbin Pingchuan Pharmaceutical
Company. TIANZHI focuses on dealing with self-produced products, as
well as dealing & distributing other medicines, health cares,
pharmaceutical apparatuses and international trade businesses
TIANZHI was authorized as the exclusive agent for the product of
Kangda'an sugar capsule in Beijing area. By the end of 2004, TIANZHI
printed out its good result that the total number of medicine
bottles sold out was 26,000 and the sales revenue in 2004 was
RMB400,000.
PGCN is
getting ready to break out. We recommend this as a VERY strong buy.
|